Accrued Liabilities - Epizyme Inc (F:EPE) - Alpha Spread
E

Epizyme Inc
F:EPE

Watchlist Manager
Epizyme Inc
F:EPE
Watchlist
Price: 559 EUR 3.33% Market Closed
Market Cap: 92.2B EUR
Have any thoughts about
Epizyme Inc?
Write Note

Epizyme Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Epizyme Inc
Accrued Liabilities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
E
Epizyme Inc
F:EPE
Accrued Liabilities
$30m
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Accrued Liabilities
$5.2B
CAGR 3-Years
-9%
CAGR 5-Years
-4%
CAGR 10-Years
5%
Amgen Inc
NASDAQ:AMGN
Accrued Liabilities
$13.7B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accrued Liabilities
$2.9B
CAGR 3-Years
26%
CAGR 5-Years
22%
CAGR 10-Years
28%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accrued Liabilities
$2.4B
CAGR 3-Years
5%
CAGR 5-Years
22%
CAGR 10-Years
26%

See Also

What is Epizyme Inc's Accrued Liabilities?
Accrued Liabilities
30m USD

Based on the financial report for Jun 30, 2022, Epizyme Inc's Accrued Liabilities amounts to 30m USD.

What is Epizyme Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
13%

Over the last year, the Accrued Liabilities growth was -11%. The average annual Accrued Liabilities growth rates for Epizyme Inc have been 13% over the past three years , 13% over the past five years .

Back to Top